» Articles » PMID: 1380673

Processing of Mutant Cystic Fibrosis Transmembrane Conductance Regulator is Temperature-sensitive

Overview
Journal Nature
Specialty Science
Date 1992 Aug 27
PMID 1380673
Citations 475
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) is a plasma membrane Cl- channel regulated by cyclic AMP-dependent phosphorylation and by intracellular ATP. Mutations in CFTR cause cystic fibrosis partly through loss of cAMP-regulated Cl- permeability from the plasma membrane of affected epithelia. The most common mutation in cystic fibrosis is deletion of phenylalanine at residue 508 (CFTR delta F508) (ref. 10). Studies on the biosynthesis and localization of CFTR delta F508 indicate that the mutant protein is not processed correctly and, as a result, is not delivered to the plasma membrane. These conclusions are consistent with earlier functional studies which failed to detect cAMP-stimulated Cl- channels in cells expressing CFTR delta F508 (refs 16, 17). Chloride channel activity was detected, however, when CFTR delta F508 was expressed in Xenopus oocytes, Vero cells and Sf9 insect cells. Because oocytes and Sf9 cells are typically maintained at lower temperatures than mammalian cells, and because processing of nascent proteins can be sensitive to temperature, we tested the effect of temperature on the processing of CFTR delta F508. Here we show that the processing of CFTR delta F508 reverts towards that of wild-type as the incubation temperature is reduced. When the processing defect is corrected, cAMP-regulated Cl- channels appear in the plasma membrane. These results reconcile previous contradictory observations and suggest that the mutant most commonly associated with cystic fibrosis is temperature-sensitive.

Citing Articles

Global functional genomics reveals GRK5 as a cystic fibrosis therapeutic target synergistic with current modulators.

Botelho H, Lopes-Pacheco M, Pinto M, Railean V, Pankonien I, Caleiro M iScience. 2025; 28(3):111942.

PMID: 40040803 PMC: 11876911. DOI: 10.1016/j.isci.2025.111942.


The arc of discovery, from the description of cystic fibrosis to effective treatments.

Welsh M J Clin Invest. 2024; 134(19).

PMID: 39352390 PMC: 11444155. DOI: 10.1172/JCI186231.


Proteostasis Landscapes of Cystic Fibrosis Variants Reveals Drug Response Vulnerability.

McDonald E, Kim M, Olson 3rd J, Olson J, Meiler J, Plate L bioRxiv. 2024; .

PMID: 39026768 PMC: 11257600. DOI: 10.1101/2024.07.10.602964.


Mutation accumulation in H. sapiens F508del CFTR countermands dN/dS type genomic analysis.

Hong J, Tindall J, Tindall S, Sorscher E PLoS One. 2024; 19(7):e0305832.

PMID: 39024311 PMC: 11257350. DOI: 10.1371/journal.pone.0305832.


Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells.

Sousa A, Hemez C, Lei L, Traore S, Kulhankova K, Newby G Nat Biomed Eng. 2024; 9(1):7-21.

PMID: 38987629 PMC: 11754097. DOI: 10.1038/s41551-024-01233-3.